- Home
- IRON vs ARWR Comparison
IRON vs ARWR Comparison
Compare IRON & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- ARWR
- Stock Information
- Founded
- IRON 2017
- ARWR 2003
- Country
- IRON United States
- ARWR United States
- Employees
- IRON N/A
- ARWR N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- ARWR Health Care
- Exchange
- IRON Nasdaq
- ARWR Nasdaq
- Market Cap
- IRON 2.1B
- ARWR 1.8B
- IPO Year
- IRON N/A
- ARWR 1993
- Fundamental
- Price
- IRON $59.76
- ARWR $15.80
- Analyst Decision
- IRON Strong Buy
- ARWR Buy
- Analyst Count
- IRON 12
- ARWR 8
- Target Price
- IRON $92.08
- ARWR $43.71
- AVG Volume (30 Days)
- IRON 330.3K
- ARWR 2.0M
- Earning Date
- IRON 08-11-2025
- ARWR 08-07-2025
- Dividend Yield
- IRON N/A
- ARWR N/A
- EPS Growth
- IRON N/A
- ARWR N/A
- EPS
- IRON N/A
- ARWR N/A
- Revenue
- IRON N/A
- ARWR $545,209,000.00
- Revenue This Year
- IRON N/A
- ARWR $22,384.93
- Revenue Next Year
- IRON N/A
- ARWR N/A
- P/E Ratio
- IRON N/A
- ARWR N/A
- Revenue Growth
- IRON N/A
- ARWR 1436.97
- 52 Week Low
- IRON $30.82
- ARWR $9.57
- 52 Week High
- IRON $68.73
- ARWR $29.47
- Technical
- Relative Strength Index (RSI)
- IRON 61.73
- ARWR 45.72
- Support Level
- IRON $58.63
- ARWR $15.51
- Resistance Level
- IRON $61.59
- ARWR $16.69
- Average True Range (ATR)
- IRON 2.15
- ARWR 1.14
- MACD
- IRON -0.14
- ARWR -0.20
- Stochastic Oscillator
- IRON 64.07
- ARWR 29.85
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.